Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous Vivaglobin in Multifocal Motor Neuropathy
2007-000710-37Phase 2Completed
- Sponsor
- CSL Behring
- Start
- Sep 2007
- Countries
- 1
01
Overview
Phase 2, single-arm trial of polyvalent human immunoglobulin in multifocal motor neuropathy (MMN), sponsored by CSL Behring. Primary endpoint: Change in muscle strength at 24 weeks. Started Sep 2007; status: completed.
02
Drugs
polyvalent human immunoglobulin
03
Conditions
multifocal motor neuropathy (MMN)
Beyond the preview
Go deeper on 2007-000710-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000710-37.